[Modification of membrane lipid of human umbilical vein endothelia cells after direct lipopolysaccharide injury].
Our previous study showed that the membrane viscosity of human umbilical vein endothelial cells (HUVECs) increased with lipopolysaccharide (LPS) concentration after direct LPS damaging, implying that LPS could change the membrane structure and composition of HUVECs. The purpose of the present study was to investigate the modification of HUVECs membrane lipid by LPS under direct LPS injury to HUVECs. Phospholipid components of HUVEC membrane were determined with high performance capillary electrophoresis (HPCE), and HUVECs were directly damaged by LPS of different concentrations: 0, 0.313, 0.625, 1.25, 2.5, 5 and 10 microgram/ml for 3 h, and by 0.625 microgram/ml for 1, 3, 6, 12, 24 and 48 h. The results show that total phospholipid content of HUVECs increased with the increase of LPS concentration at 3 h, and decreased with the duration of LPS effect at 0.625 microgram/ml. Phosphatidylinositol (PI) and phosphatidylcholine (PC) contents increased with the increase of LPS concentration and decreased with the duration of LPS effect; LPS contents and its effect duration had slight effect on sphingomyelin (SM), phosphatidylethanolamine (PE) or phosphatidylserine (PS) contents. The LPS activating effect of HUVEC membrane lipid showed a typical property of enzymatic dynamics. These experimental results indicate that LPS directly activates the metabolism of HUVEC membrane lipid and induces the modification of HUVEC membrane phospholipid, which implies that the mechanism of the impairment of HUVECs by LPS may be related to the membrane structure of HUVECs and the metabolism of HUVEC membrane lipid.
Wang
X
X
Bioengineeing College of Chongqing University, The Open Laboratory for Biomechanics and Biorheology Under the Ministry of Education, Chongqing 400044; xwangchn@cqu.edu.cn
Cai
S X
SX
Luo
X D
XD
Wang
P
P
Luo
Q
Q
Liang
G P
GP
Yang
Z C
ZC
D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008563:Membrane Lipids / Q000378:metabolism*; D014471:Umbilical Veins / Q000166:cytology
D008070:Lipopolysaccharides; D008563:Membrane Lipids